JP
VRTX icon

John Paulson’s Vertex Pharmaceuticals VRTX Stock Holding History

John Paulson’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-61,500
Closed -$4.89M – 98
2016
Q1 		$4.89M Buy
61,500
+15,100
+33% +$1.37M 0.04% 69
2015
Q4 		$5.84M Buy
+46,400
New +$5.6M 0.03% 55

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

John Paulson's VRTX Position: Q2 2016 in Review

John Paulson sold out of Vertex Pharmaceuticals (VRTX) in Q2 2016, closing a stake of 61,500 shares — an estimated $4.89M sold.

John Paulson first reported a position in VRTX in Q4 2015 and held it in 2 quarters. The position peaked at $5.84M in Q4 2015. 483 funds tracked by Wall St. Rank hold VRTX as of Q2 2016.

  • John Paulson reported no remaining Vertex Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • John Paulson sold 61,500 Vertex Pharmaceuticals shares in Q2 2016, an estimated $4.89M.
  • John Paulson first reported a position in Vertex Pharmaceuticals in Q4 2015 and held it in 2 quarters.
  • John Paulson's Vertex Pharmaceuticals position peaked at $5.84M in Q4 2015.
  • 483 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2016.

Based on Paulson & Co's 13F filing for Q2 2016, filed 15 Aug 2016.